These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17477808)

  • 1. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
    Rainov NG; Tsuboi Y; Krolak-Salmon P; Vighetto A; Doh-Ura K
    Expert Opin Biol Ther; 2007 May; 7(5):713-26. PubMed ID: 17477808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.
    Todd NV; Morrow J; Doh-ura K; Dealler S; O'Hare S; Farling P; Duddy M; Rainov NG
    J Infect; 2005 Jun; 50(5):394-6. PubMed ID: 15907546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models.
    Doh-ura K; Ishikawa K; Murakami-Kubo I; Sasaki K; Mohri S; Race R; Iwaki T
    J Virol; 2004 May; 78(10):4999-5006. PubMed ID: 15113880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion.
    Honda H; Sasaki K; Minaki H; Masui K; Suzuki SO; Doh-Ura K; Iwaki T
    Neuropathology; 2012 Apr; 32(2):124-32. PubMed ID: 21801238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.
    Tsuboi Y; Doh-Ura K; Yamada T
    Neuropathology; 2009 Oct; 29(5):632-6. PubMed ID: 19788637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.
    Terada T; Tsuboi Y; Obi T; Doh-ura K; Murayama S; Kitamoto T; Yamada T; Mizoguchi K
    Acta Neurol Scand; 2010 Feb; 121(2):127-30. PubMed ID: 19804470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate.
    Newman PK; Todd NV; Scoones D; Mead S; Knight RS; Will RG; Ironside JW
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):921-4. PubMed ID: 24554103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases.
    Larramendy-Gozalo C; Barret A; Daudigeos E; Mathieu E; Antonangeli L; Riffet C; Petit E; Papy-Garcia D; Barritault D; Brown P; Deslys JP
    J Gen Virol; 2007 Mar; 88(Pt 3):1062-1067. PubMed ID: 17325382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.
    Parry A; Baker I; Stacey R; Wimalaratna S
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):733-4. PubMed ID: 17314188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered properties of amyloidogenic prion protein in genetic Creutzfeldt-Jakob disease with PRNP V180I mutation in response to pentosan polysulfate.
    Shijo M; Yoshimura M; Omae T; Hashimoto G; Mizoguchi T; Kuwashiro T; Komori T; Tsuboi Y; Saito T; Nakagawa M; Itoh K; Honda H
    Brain Pathol; 2023 Sep; 33(5):e13197. PubMed ID: 37525413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK.
    Bone I; Belton L; Walker AS; Darbyshire J
    Eur J Neurol; 2008 May; 15(5):458-64. PubMed ID: 18355301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Part II].
    Zaborowski A
    Psychiatr Pol; 2004; 38(2):297-309. PubMed ID: 15307294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental treatment may show promise for vCJD.
    Pincock S
    Lancet; 2003 Oct; 362(9390):1130. PubMed ID: 14558510
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy in prion diseases.
    Forloni G; Artuso V; Roiter I; Morbin M; Tagliavini F
    Curr Top Med Chem; 2013; 13(19):2465-76. PubMed ID: 24059336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease.
    Dealler S; Rainov NG
    IDrugs; 2003 May; 6(5):470-8. PubMed ID: 12789602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies.
    Farquhar C; Dickinson A; Bruce M
    Lancet; 1999 Jan; 353(9147):117. PubMed ID: 10023899
    [No Abstract]   [Full Text] [Related]  

  • 17. Human transmissible spongiform encephalopathies: historic view.
    Asher DM; Gregori L
    Handb Clin Neurol; 2018; 153():1-17. PubMed ID: 29887130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentosan in transmissible spongiform encephalopathies.
    Deli MA; Niwa M; Katamine S; Abrahám CS
    Lancet; 1999 Apr; 353(9160):1272. PubMed ID: 10217107
    [No Abstract]   [Full Text] [Related]  

  • 19. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.
    Whittle IR; Knight RS; Will RG
    Acta Neurochir (Wien); 2006 Jun; 148(6):677-9; discussion 679. PubMed ID: 16598408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prions: a mystery unravelled?
    Cavallo G; Lembo D; Cavallo R
    Riv Biol; 2010; 103(2-3):343-70. PubMed ID: 21384329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.